ChatGPT-Assisted Machine Learning for Chronic Disease Classification and Prediction: A Developmental and Validation

Sumira Abbas1, Mahwish Iftikhar2, Mian Mufarih Shah2

  • 1Department of Pathology, Peshawar Medical College, Peshawar, PAK.

Cureus
|January 17, 2025
PubMed

Insights

Machine learning models, including random forest, show promise for predicting chronic diseases like CKD and heart disease. ChatGPT assisted in optimizing these models for better accuracy and feature selection.

Area of Science:

  • Medical Informatics
  • Computational Biology
  • Machine Learning in Healthcare

Background:

  • Chronic diseases (CKD, CLD, TB, dementia, heart disease) are major global health issues.
  • Early diagnosis and intervention are crucial for improving patient outcomes and reducing healthcare costs.

Purpose of the Study:

  • To evaluate the efficacy of machine learning (ML) models in classifying and predicting chronic diseases.
  • To explore the role of ChatGPT in enhancing ML model development for disease prediction.

Main Methods:

  • A prospective observational study involving 260 patients across five chronic disease categories.
  • Utilized logistic regression, random forest, and support vector machines, with ChatGPT assisting in feature selection and hyperparameter optimization.
  • Employed 10-fold cross-validation and evaluated models using accuracy, sensitivity, specificity, precision, recall, F1-score, and AUC-ROC.

Main Results:

  • The random forest model achieved high accuracy in predicting CKD (85.3%) and heart disease (88.2%).
  • Logistic regression effectively predicted TB (80.1%) and dementia (82.4%).
  • Hemoglobin and erythrocyte sedimentation rate were identified as key predictive parameters.

Conclusions:

  • Machine learning algorithms, particularly random forest, demonstrate significant potential for chronic disease classification and prediction.
  • ChatGPT integration improved ML model development through optimized feature selection and hyperparameter tuning.
  • Future research should prioritize external validation via multi-center studies and prospective clinical trials.